Clinical trials in Montpellier – page 59

1 094 clinical trials in Montpellier, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Montpellier at a glance

1 094

clinical trials

Research sites4

Quick filters

1 094 trials in Montpellier

Open in trial search

Gastrointestinal carcinoma

Not recruiting

Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Kite Pharma Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug

Study of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Salbutamol
Sponsor:AstraZeneca AB

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational

France

Participants:18–64 years
Substances:Frexalimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Asthma

Not recruiting

Study on Tezepelumab for Patients with Severe Asthma

Registered drug

Study on Tezepelumab for Patients with Severe Asthma

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Tezepelumab
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational

France

Participants:18–64 years
Substances:Tolebrutinib
Sponsor:Genzyme Corp.

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Acerta Pharma B.V.

Contact Research Centre

Metastatic renal cell carcinoma

Not recruiting

Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

Registered drugNo placebo

Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Centre Hospitalier Universitaire De Bordeaux

Contact Research Centre

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Pfizer Inc.

Contact Research Centre

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Allogeneic Faecal Microbiota, Pooled
Sponsor:Maat Pharma

Contact Research Centre

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Prasinezumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Montpellier

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, bladder cancer, and mantle cell lymphoma. Studies evaluate combination therapies and novel treatment approaches for improved patient outcomes.

Advanced HNSCC Treatment Combinations
Non-muscle Invasive Bladder Cancer Therapy
Gastric Cancer Targeted Treatments

Research includes evaluation of immunotherapy combinations and targeted molecular approaches.

02 Autoimmune Conditions

Studies examining innovative treatments for Crohn's disease, multiple sclerosis, and systemic sclerosis. Research focuses on novel therapeutic approaches and treatment optimization.

Fecal Microbiota Transplantation Studies
MS Treatment De-escalation Strategies
Advanced Autoimmune Therapies

Trials aim to improve disease management and patient quality of life.

03 Rare Diseases

Investigating treatments for achondroplasia, pyruvate dehydrogenase deficiency, and thyroid eye disease. Focus on developing targeted therapies for these uncommon conditions.

Growth Disorders in Children
Metabolic Disease Management
Innovative Therapeutic Approaches

Research aims to address unmet medical needs in rare disease populations.

04 Preventive Medicine

Clinical trials evaluating vaccines for cytomegalovirus, yellow fever, and HPV prevention. Studies focus on immunization effectiveness and safety profiles.

Vaccine Development Programs
Infection Prevention Strategies
Population Health Protection

Research emphasizes disease prevention and public health improvement.

Back to France All countries